Efficacy and Safety of Keratosept Eye Drops in Patients with Punctate Keratitis: Clinical and Microbiological Evaluation on 50 Eyes.

We evaluated the efficacy and safety of eye drops with antiseptic and re-epithelizing properties (Keratosept, Bruschettini, Genova, Italy) on 50 eyes affected by punctate keratitis of suspected microbial origin. A biomicroscopic examination, fluorescein dye staining test (Fluotest), tear break-up time test (TBUT), and the ocular surface disease Index (OSDI) questionnaire were used to assess treatment efficacy. Treatment success was defined as a negative Fluotest and an OSDI score <12 on the 15th day of treatment.

Essential infantile esotropia with inferior oblique hyperfunction: long term follow-up of 6 muscles approach.

Aim: To evaluate long term follow-up (10y) of 6 muscle surgical approach in essential infantile esotropia (EIE).

Methods: A 6 muscle approach to EIE was retrospectively evaluated in patients with inferior oblique (IO) hyperfunction and lateral rectus (LR) pseudoparalysis, who underwent surgery at different ages. Different clinical characters were analyzed pre- and postoperatively, in patients who underwent a 6 muscles approach ≤4 years of age.

Congenital and Developmental Cataracts: Focus on Strabismus Outcomes at Long-Term Follow-Up.

Purpose: To evaluate the incidence of strabismus in congenital and developmental cataract surgery in patients with a follow-up longer than five years.

Methods: All patients with congenital and developmental cataracts observed from 1996 to 2013 with a follow-up longer than five years were retrospectively included.

Results: We included 117 patients (58 females and 59 males, mean age 0.

Pediatric keratoconus and iontophoretic corneal crosslinking: refractive and topographic evidence in patients underwent general and topical anesthesia, 18 months of follow-up.

To evaluate the efficiency and safety of iontophoretic transepithelial corneal crosslinking in pediatric patients with progressive keratoconus underwent general or topical anesthesia in 18 months follow-up. 13 patients (13 eyes) diagnosed with progressive keratoconus underwent corneal CXL with iontophoresis (I-CXL). Riboflavin solution was administered by iontophoresis for 5 min, and then UV-A irradiation (10 mW/cm) was performed for 9 min.

Evaluation of ischemic diabetic maculopathy with Fourier-domain optical coherence tomography and microperimetry.

Objective: To evaluate the efficacy of high-speed Fourier-domain optical coherence tomography (FD-OCT) and fundus microperimetry (MP-1) in identifying the anatomic and functional features of ischemic diabetic maculopathy.

Design: Prospective noninterventional study.

Participants: Forty-two consecutive eyes (23 patients) with ischemic diabetic maculopathy and 40 normal eyes (25 control subjects) were included in this study.

Functional and anatomic changes in bilateral choroidal neovascularization associated with vitelliform macular dystrophy after intravitreal bevacizumab.

Purpose: We report the case of a young man with choroidal neovascularization (CNV) associated with vitelliform macular dystrophy (Best's disease), who underwent treatment with intravitreal bevacizumab.

Case: A 17-year-old white male presented for a routine ocular examination after reduction of visual acuity and was diagnosed with CNV in both eyes secondary to Best's disease. The diagnosis was confirmed by an ophthalmologic examination that included fluorescein angiography, indocyanine green angiography, Fourier optical coherence tomography, and microperimetry.

Functional and anatomic response of the retina and the choroid to intravitreal bevacizumab for macular edema.

Purpose: This study evaluated the rate of change of best corrected visual acuity (BCVA), central retinal sensitivity, and retinal and choroidal thickness in patients with macular edema after intravitreal bevacizumab.

Methods: This was a prospective, nonrandomized, interventional study. Thirty-four consecutive eyes (34 patients) with macular edema were included in the study.

Bevacizumab in macular edema: functional and anatomic changes in a prospective case series.

Objective: To evaluate the early rate of change of best-corrected visual acuity (BCVA), central retinal sensitivity, neuroretinal and choroidal thickness in patients with macular edema after 1.25 mg/0.05 ml intravitreal bevacizumab (Avastin; Genentech, Inc.